Wegovy paediatric dosing: the UK licensing facts, clearly explained

The misconception worth correcting first: trial results are not the same as a licence

A common assumption runs like this: semaglutide has shown results in paediatric trials, so a dosing schedule must exist somewhere. It does not, not in the UK. The MHRA has not granted Wegovy a paediatric indication, which means prescribing it to someone under 18 would be off-label, requiring specific clinical justification and governance that a standard online consultation cannot provide.

The confusion is understandable. In the United States, the FDA approved semaglutide 2.4mg for adolescents aged 12 and over in December 2023, following the STEP TEENS trial. That trial enrolled adolescents with obesity and reported meaningful average weight reduction compared with placebo. However, an FDA approval carries no automatic authority in the UK. The MHRA runs its own independent assessment process, and as of summer 2026 no equivalent paediatric approval has been granted here. If you have read US-focused content and arrived looking for a UK route, this page should save you a frustrating search.

For a fuller picture of how semaglutide dosing works in licensed adult use, the semaglutide dosing guide covers the adult schedule in detail.

What the adult Wegovy licence does cover, and why the age boundary matters clinically

In adults, Wegovy is licensed for BMI 30 or above, or 27 or above alongside at least one weight-related condition such as high blood pressure or sleep apnoea. The titration pathway starts at 0.25mg weekly and steps up roughly every four weeks, reaching 2.4mg as the standard maintenance dose, with a higher 7.2mg dose now also approved for eligible adults. None of that schedule has been validated by the MHRA for a developing body, which is precisely why the age boundary exists.

Paediatric pharmacology is not simply adult dosing scaled down. Absorption, metabolism and hormonal context differ in children and adolescents, and clinical trials in adults cannot be extrapolated safely to younger patients without dedicated paediatric studies. The semaglutide paediatric approval tracker covers the regulatory status in more depth, including what a future UK application process might look like and what the STEP TEENS data showed.

For adults exploring what Wegovy involves before their consultation, the Wegovy dosing overview and the Wegovy dosing chart both set out the adult titration schedule clearly. Those pages are not relevant to paediatric use, but they are useful context for parents who are themselves considering treatment.

Where families should turn if a young person needs support with weight

Weight management in children and teenagers is handled through very different clinical pathways from adult services. In England, Tier 3 and Tier 4 specialist paediatric weight management services exist through the NHS, and referrals go through a GP. NICE guideline NG246, which covers overweight and obesity management across the life course, includes specific recommendations for children and young people that do not involve GLP-1 medicines as a first step.

If you are a parent, the right conversation starts with your child's GP. If you are a clinician looking for the current evidence on semaglutide paediatric dosing in the context of an off-label decision, the BNF and the relevant MHRA communications are the appropriate starting point, not an online pharmacy service. Our pharmacy and prescribers are GPhC-registered and MHRA-regulated, and you can read about the clinical team on the clinical team page. We are set up for adult weight-management consultations only.

That boundary is not a commercial one. It reflects the licence. Prescribing outside a licence to a minor, for weight management, without the appropriate specialist paediatric governance, would not meet the standard of care our prescribers uphold. Every prescription issued by a real clinician at this pharmacy rests on a full clinical assessment, not a checkbox. That is why the cost of Wegovy through a regulated private service reflects what genuine clinical oversight actually involves.

What to do if you are an adult looking for Wegovy treatment through a regulated UK pharmacy

If you arrived at this page because you are an adult exploring weight-management options and the word "paediatric" crept into your search, the short answer is: the adult route is well-established and straightforward. Wegovy is available through private prescription following clinical assessment. A prescriber reviews your consultation the same day, which means that if you submit before noon on a working day and are found clinically suitable, your treatment can leave our GPhC-registered pharmacy with DPD that afternoon, arriving in plain packaging the next working day.

The Wegovy information page covers the full adult picture, from how the medicine works to what the licensed results look like. The Wegovy dosing for weight loss page addresses common adult questions about the schedule. And if you want to compare the options available, the weight-loss treatment overview sets them out side by side.

For any adult ready to start, speaking to our prescribers is the next step. The consultation is free, there is no subscription and no hidden fees, and the clinical review is carried out by a GPhC-registered Independent Prescriber. Speak to our prescribers to begin your free consultation.